◆英語タイトル:MarketVIEW: E.coli (ExPEC) vaccines - Global vaccine overview
◆発行会社(調査会社):VacZine Analytics
Executive Presentation (PDF)GBP3,000 ⇒換算¥402,000見積依頼/購入/質問フォーム
Forecast Model (Excel)GBP3,000 ⇒換算¥402,000見積依頼/購入/質問フォーム
PDF+ExcelGBP6,000 ⇒換算¥804,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規販売代理店です。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。


Extra intestinal pathogenic E.coli (ExPEC) is a member of the Enterobacteriaceae bacterial family. It is a leading cause of healthcare-associated (HCA) infections such as bacteraemia, urinary tract infections, neonatal sepsis and meningitis. For bacteraemias, based on a principal diagnosis from US hospital discharge data, there were an 96,560 E. coli bacteraemias in 2013 compared to 46,140 in 2000, an increase of 109%1 Although the number Streptococcal, Staphylococcal and Pneumococcal bacteraemias also increased over the same time period, in 2009, E. coli overtook Staphylococcus as the leading cause of bacteraemia. Importantly, carbapenem-resistant E. coil is also considered an “urgent” threat according to the US CDC. E.coli is also a common cause of community-acquired, uncomplicated UTIs, which are a common cause of US emergency department and primary care visits. According to NHANES III, around 12% of women reported a UTI in the last 12 months.

Currently there is no vaccine to prevent ExPEC infections. Janssen Pharmaceuticals is co-developing JNJ-860/EcoXyn-4V, a 4- valent “O” antigen conjugate vaccine (the O antigen forms part of the E. coli lipopolysaccharide), currently in Phase II development. Other approaches such as subunit or whole vaccines have under investigation but not currently in active development.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of ExPEC vaccines across major Western to 2035. Indications considered are prevention of invasive ExPEC disease in ]18 yrs (risk and non-risk) and prevention of recurrent UTIs in females 18-64 yrs.The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon the level of populations targeted by a potential vaccine.




****This product is composed of two forecast models and a summary presentation

Title page
Author’s note
Executive summary
ExPEC vaccines: Commercial model: key outputs
ExPEC vaccines: sales by scenario (base pricing) to 2030
ExPEC vaccines: sales by scenario (low pricing) to 2030
ExPEC vaccines: sales by scenario (high pricing) to 2030
Modelling commercial potential
The role of an ExPEC vaccine
ExPEC: disease associations
ExPEC vaccine: potential indications
ExPEC vaccine: potential target populations
ExPEC vaccine target product profile (TPP)
Key model assumptions
Key model assumptions: scenarios
Pricing assumptions: disease burden comparisons
Pricing assumptions: bacteraemias – comparator table
ExPEC – Disease background and epidemiology
The pathogen
Pathogenic types
E.coli and bacteraemias
Bacteraemias: hospital admissions – US, 2000-2013
Bacteraemias: by age group US, 2013
Bacteraemias: mortality, United Kingdom
Bacteraemias: UK comparison to other hospital pathogens
Bacteraemias: by age and gender, England
Bacteraemias: sources of, England
Bacteraemias: community-acquired, England
Bacteraemias: France
Bacteraemias: France, clinical characteristics
E.coli: infant sepsis and meningitis
E.coli and healthcare-associated infections
Urinary tract infections, uncomplicated
Urinary tract infections, uncomplicated: US burden
Urinary tract infections, uncomplicated: hospitalization
Urinary tract infections, uncomplicated: treatment
Urinary tract infections, uncomplicated: recurrence
Urinary tract infections, uncomplicated: impact
E. coli antibiotic resistance trends
E.coli – antibiotic resistance trends: global dynamics
E.coli – antibiotic resistance trends (WHO report)
EU E.coli – antibiotic resistance trends (1)
EU E.coli – antibiotic resistance trends (2)
ExPEC vaccines: R&D pipeline
Vaccine R&D pipeline: overview
Vaccine R&D pipeline: JNJ-860/EcoXyn-4V
Target risk groups for JNJ-860/EcoXyn-4V vaccine
JNJ-860/EcoXyn-4V vaccine: status
Vaccine R&D pipeline: relevance E. coli O serotypes
Vaccine R&D pipeline: other HAI infection targets
Vaccine R&D pipeline: potential clinical strategy
ExPEC vaccines: methodology
Vaccine coverage rates: case studies
Vaccine coverage rates: private self-pay
Vaccine coverage rates: pneumovax benchmarks
Demographic and epidemiological model inputs
VacZine Analytics

*** PAGES: ~67 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form





※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年10月27日現在 208,454 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。